Moderate To Severe Acute Pain Market Size (7MM) is expected to grow at a significant CAGR During the forecast period of 2025-2034 | DelveInsight

DelveInsight's "Moderate To Severe Acute Pain Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of the Moderate To Severe Acute Pain, historical and forecasted epidemiology and the Moderate To Severe Acute Pain Market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Moderate To Severe Acute Pain Market Report @ https://www.delveinsight.com/report-store/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Moderate To Severe Acute Pain Market Report
• The Moderate To Severe Acute Pain market in the 7MM was valued at approximately USD 4,536 million in 2025 and is projected to reach USD 13,579 million in 2034, growing at a CAGR of 13.00% over the forecast period.
• Among the 7MM, the US captured the highest Moderate to Severe Acute Pain Market in 2024, covering nearly USD 3,500 million, followed by Germany, which is anticipated to grow during the forecast period.
• In the 7MM, the US accounted for the highest number of incident cases of acute pain, with nearly 86,800,000 cases in 2024.
• Among EU4 and the UK, the maximum cases were reported in Germany, followed by France, and the least cases were found in Spain.
• In the US, about 40% of cases observed were of moderate acute pain, and 20% for severe acute pain.
• Japan accounted for about 8,419,000 cases of moderate acute pain and about 2,078,000 cases of severe acute pain, in 2024.
• The Moderate To Severe Acute Pain Companies include Vertex Pharmaceuticals, Ocular Therapeutix, Heron Therapeutics, Bausch & Lomb, Satsuma Pharmaceuticals, Axsome Therapeutics, Eli Lilly, Pfizer, Scilex Holding, AbbVie, Amneal Pharmaceuticals, and others.
• Promising Moderate To Severe Acute Pain Therapies include JOURNAVX (suzetrigine), mdc-CWM (F14), OCS-01, NTM-001, cebranopadol (TRN-228), LTG-001, and others.

Get a Free sample for the Moderate To Severe Acute Pain Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Recent Developments in the Moderate To Severe Acute Pain Market
• In August 2025, Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. launched a clinical study to assess the safety, efficacy, and pharmacokinetic (PK) profile of the HL-1186 tablet in patients with moderate to severe acute postoperative pain.

What is Moderate To Severe Acute Pain?
Acute pain is a sensory response to tissue damage or dysfunction that appears suddenly, often due to injury, surgery, or infection, and usually resolves within three months. Its perception varies widely between individuals depending on differences in nerve signaling and brain processing. It ranges from mild, self-limiting conditions like headaches or muscle strains to severe trauma requiring hospitalization and surgical intervention. Treatment depends on severity, ranging from over-the-counter analgesics and rest to stronger medications like opioids for intense pain. Pain can present as stabbing, dull, aching, throbbing, or tingling, and can disrupt sleep, appetite, and emotional well-being, and may lead to psychological effects or medication dependence if left unaddressed.

Moderate To Severe Acute Pain Epidemiology Segmentation in the 7MM
• Total Incident Cases of Acute Pain
• Total Diagnosed Incident Cases of Acute Pain
• Severity-specific Diagnosed Incident Cases of Acute Pain

Download the report to understand which factors are driving Moderate To Severe Acute Pain epidemiology trends @ https://www.delveinsight.com/report-store/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Moderate To Severe Acute Pain Approved Therapies
• JOURNAVX (suzetrigine): Vertex Pharmaceuticals
JOURNAVX is a first-in-class, oral, nonopioid, highly selective pain signal inhibitor selective for NaV1.8 relative to other NaV channels. Because JOURNAVX blocks pain signals only found in the periphery, not in the brain, it provides effective relief without the limitations of currently available therapies, including the addictive potential of opioids. In January 2025, the US FDA approved JOURNAVX to treat moderate-to-severe acute pain in adults, and its US launch is currently underway.

• ATZUMI (dihydroergotamine): Satsuma Pharmaceuticals
ATZUMI nasal powder is the first and only DHE nasal powder indicated for the acute treatment of migraine with or without aura in adults, delivered through a convenient, portable device using the proprietary SMART (Simple MucoAdhesive Release Technology) platform. In April 2025, the US FDA approved ATZUMI for this indication.

Moderate To Severe Acute Pain Pipeline Analysis
• mdc-CWM (F14): MedinCell/Arthritis Innovation Corporation (AIC)
F14 is a sustained-release formulation of the NSAID celecoxib, designed to reduce pain and inflammation and enhance recovery after total knee replacement (TKR). It is administered into the intra-articular space at the end of TKR surgery and may provide pain relief over several weeks post-surgery, currently under evaluation in a Phase III trial.

• LTG-001: Latigo Biotherapeutics
LTG-001 is an oral, investigational selective inhibitor of Nav1.8, a key sodium channel involved in pain signaling, working by blocking peripheral sensory neurons responsible for pain signals. In March 2025, the US FDA granted Fast Track Designation to LTG-001 following positive Phase I safety, tolerability, and pharmacokinetic results.

Moderate To Severe Acute Pain Companies
Vertex Pharmaceuticals, Ocular Therapeutix, Heron Therapeutics, Bausch & Lomb, Satsuma Pharmaceuticals, Axsome Therapeutics, Eli Lilly, Pfizer, Scilex Holding, AbbVie, Amneal Pharmaceuticals, Cali Biosciences, Tris Pharma, Neumentum, Viatris, Taiwan Liposome (TLC BioSciences), Allay Therapeutics and Maruishi Pharmaceutical, Latigo Biotherapeutics, and others

Discover more about therapies set to grab major Moderate To Severe Acute Pain market share @ https://www.delveinsight.com/sample-request/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Moderate To Severe Acute Pain Market Outlook
The current treatment approach for Moderate to Severe Acute Pain consists of pharmacological and non-pharmacological methods. Pharmacological treatments include analgesics such as opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, corticosteroids, and anesthetics, alongside benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, GABA agonists, and cannabinoids. The WHO's three-step pain ladder guides treatment from non-opioids and non-drug methods to low-dose opioids, then stronger opioids or invasive options for severe pain, with modified versions allowing steps to be skipped for intense pain. Multimodal analgesia, combining therapies acting at various pain pathways, can improve relief, reduce opioid use, and support recovery activities such as mobility and rehabilitation.

Local anesthetics are preferred for preoperative and intraoperative pain management, though postoperative use is limited by duration; long-acting anesthetics like EXPAREL offer extended relief supported by adjuvants such as epinephrine. NSAIDs, commonly prescribed after surgery, reduce opioid use by up to 50%, while combination therapies like ZYNRELEF and SEGLENTIS enhance efficacy while minimizing opioid reliance. ZYNRELEF provides up to 72 hours of relief and is gaining traction in the US. Innovations such as DEXTENZA and JOURNAVX offer long-lasting, non-opioid options for specific conditions, while EXPAREL remains a leading choice for post-surgical pain relief. The Market is expected to experience positive growth with the approval of potential drugs like mdc-CWM (F14), OCS-01, MR-301, TK-254Rx, DEPADE, and others, with NURTEC ODT/VYDURA (rimegepant) expected to capture the highest Market share among forecasted emerging therapies by 2034.

Scope of the Moderate To Severe Acute Pain Market Report
• Study Period: 2020-2034
• Forecast Period: 2025-2034
• Coverage: 7MM
• Moderate To Severe Acute Pain Companies: Vertex Pharmaceuticals, Ocular Therapeutix, Heron Therapeutics, Bausch & Lomb, Satsuma Pharmaceuticals, Axsome Therapeutics, and others
• Moderate To Severe Acute Pain Therapies: JOURNAVX (suzetrigine), COMBOGESIC IV/MAXIGESIC IV, DEXTENZA (dexamethasone), INVELTYS, LOTEMAX SM, EXPAREL, and others
• Moderate To Severe Acute Pain Therapeutic Assessment: Moderate To Severe Acute Pain current marketed and emerging therapies
• Moderate To Severe Acute Pain Market Dynamics: Moderate To Severe Acute Pain market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• Moderate To Severe Acute Pain Unmet Needs, KOL's views, Analyst's views, Moderate To Severe Acute Pain Market Access and Reimbursement

To know more about Moderate To Severe Acute Pain companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/moderate-to-severe-acute-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Moderate-to-Severe Acute Pain Market Overview at a Glance
7. Disease Background and Overview
8. Treatment Guidelines
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Therapies
12. Emerging Drugs
13. Moderate-to-Severe Acute Pain: The Seven Major Market Analysis
14. Unmet Needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.